Features of assessing the condition of pregnant women with parathyroid adenoma

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2026.82.26-33

Keywords:

pregnant women, parathyroid glands, hyperparathyroidism, diagnosis, vitamin D

Abstract

The relevance of this topic lies in the lack of reliable statistical data in available literature regarding the incidence of parathyroid gland disorders in pregnant women and

the differences in diagnosis and therapy during pregnancy versus outside of pregnancy. A physician’s knowledge of the physiological changes that occur in a woman’s

body during pregnancy, including mineral metabolism and endocrine gland function, facilitates accurate and timely differential diagnosis between parathyroid tumors, physiological processes, and symptoms of gestational complications.

Differential diagnosis of parathyroid pathology from gestational processes at various stages of pregnancy is complex. Timely detection of parathyroid pathology is particularly important at the stage of pregnancy planning. Differential diagnosis of parathyroid adenoma is carried out in comparison with gestational processes, including gestational complications such as nausea and vomiting in pregnant women. Late diagnosis of clinical manifestations of parathyroid pathology in pregnancy can lead to severe consequences for both the mother and the fetus. For this reason, in clinical practice, timely detection of parathyroid pathology during the pregnancy planning stage is essential.

Examination of pregnant women and determination of therapeutic interventions should be multidisciplinary, personalized, and include measurement of blood levels of thyroid-stimulating hormone, vitamin D, calcium, magnesium, phosphorus, and parathyroid hormone.

Therapeutic options for hyperparathyroidism in pregnant women are limited. A personalized and multidisciplinary approach is essential in each individual case. Women with parathyroid tumors require individualized, qualified monitoring during both the early and late postpartum periods and during lactation, as there is always a risk of hypercalcemia. Administration of vitamin D should be carried out under laboratory control of its blood levels in pregnant women and should be personalized, taking into account the gestational age.

In newborns of mothers with parathyroid tumors, it is necessary to monitor calcium levels in both blood and urine.

Author Biographies

V.P. Mishchenko, Odesa National Medical University, Odesa

DSc, professor, Department of Obstetrics and Gynecology

I.Z. Gladchuk, Odesa National Medical University, Odesa

DSc, professor, head of the Department of Obstetrics and Gynecology

V.V. Mishchenko, Odesa National Medical University, Odesa

DSc, professor, Department of Surgery, Radiation Diagnostics, Radiation Medicine, Therapy and Oncology

References

  1. Appelman-Dijkstra NM, Pilz S. Approach to the Patient: Management of Parathyroid Diseases Across Pregnancy. J Clin Endocrinol Metab. 2023 May 17;108(6):1505–13. DOI: 10.1210/clinem/dgac734.
  2. Augustin G, Lai Q, Cigrovski Berkovic M. Primary hyperparathyroidism-induced acute pancreatitis in pregnancy: A systematic review with a diagnostic-treatment algorithm. World J Gastroenterol. 2024 Aug 28;30(32):3755-3765. DOI: 10.3748/wjg.v30.i32.3755.
  3. Beck AJ, Reddy VM, Sulkin T, Browne D. Management of severe and symptomatic primary hyperparathyroidism in the first trimester of unplanned pregnancy. Endocrinol Diabetes Metab Case Rep. 2022 Sep 1;2022:21-0203. DOI: 10.1530/EDM-21-0203.
  4. Anastasilakis AD, Yavropoulou MP, Kassi E, Adamidou F, Vryonidou A, Tournis S, et al. Diagnosis and management of primary hyperparathyroidism: recommendations from the Bone Section of the Hellenic Endocrine Society. Hormones (Athens). 2025 Dec;24(4):905–912. DOI: 10.1007/s42000-025-00681-z
  5. Bandeira F, de Moura Nóbrega J, de Oliveira LB, Bilezikian J. Medical management of primary hyperparathyroidism. Arch Endocrinol Metab. 2022 Nov 11;66(5):689–93. DOI: 10.20945/2359-3997000000558.
  6. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022 Nov;37(11):2293–314. DOI: 10.1002/jbmr.4677
  7. Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, et al. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022 Jan 13;186(2):R33–R63. DOI: 10.1530/EJE-21-1044.
  8. Cardoso LM, Rolighed L, Amrein K, Pilz S, Underbjerg L, Pretorius M, et al. Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders. Eur J Endocrinol. 2025 Nov 26;193(6):R65–R88. DOI: 10.1093/ejendo/lvaf204.
  9. Chan SY, Marsh MS, Gilbert J, Boelaert K, Evans C, Dhillon-Smith R, et al. Management of Thyroid Disorders in Pregnancy: Green-top Guideline No. 76. BJOG. 2025 Jul;132(8):e130–e161. DOI: 10.1111/1471-0528.18088
  10. Dumitrascu MD, Petrova E, Rentea DE, Zugravu S, Ghemigian A, Carsote M, et al. Parathyroid adenoma versus primary hyperparathyroidism. Ro Med J. 2021;68(4):477–81. DOI: 10.37897/RMJ.2021.4.12
  11. El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu JM, Minisola S, et al. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism. J Bone Miner Res. 2022 Nov;37(11):2330–50. DOI: 10.1002/jbmr.4679
  12. Esposito M, Paulesu L, Mandalà M. The role of placental hormones and metabolites in modulating uterine circulation in physiological and pathological pregnancies. Front Endocrinol (Lausanne). 2025 Aug 19;16:1637570. DOI: 10.3389/fendo.2025.1637570
  13. Cetani F, Pardi E, Marcocci C. Parathyroid Carcinoma and Ectopic Secretion of Parathyroid hormone. Endocrinol Metab Clin North Am. 2021 Dec;50(4):683–709. DOI: 10.1016/j.ecl.2021.07.001.
  14. Galani A, Morandi R, Dimko M, Molfino S, Baronchelli C, Lai S, et al. Atypical parathyroid adenoma: clinical and anatomical pathologic features. World J Surg Oncol. 2021 Jan 20;19(1):19. DOI: 10.1186/s12957-021-02123-7
  15. Glasgow C, Lau EYC, Aloj L, Harper I, Cheow H, Das T, et al. An Approach to a Patient With Primary Hyperparathyroidism and a Suspected Ectopic Parathyroid Adenoma. J Clin Endocrinol Metab. 2022 May 17;107(6):1706–13. DOI: 10.1210/clinem/dgac024.
  16. Eremkina A, Bibik E, Mirnaya S, Krupinova J, Gorbacheva A, Dobreva E, et al. Different treatment strategies in primary hyperparathyroidism during pregnancy. Endocrine. 2022 Sep;77(3):556–60. DOI: 10.1007/s12020-022-03127-3
  17. Gonçalves J, Freitas G, Souto SB, Rodrigues T, Couto PS, Belo S, Queirós J. Pregnancy Complicated by Primary Hyperparathyroidism-A Case Report on the Use of Cinacalcet. Clin Case Rep. 2025 Mar 5;13(3):e70305. DOI: 10.1002/ccr3.70305
  18. Farwick AL, Bačinović M, Heizmann O, Meinhardt A. [Two cases of complicated primary hyperparathyroidism during pregnancy]. Inn Med (Heidelb). 2026 Apr;67(4):467–71. German. DOI: 10.1007/s00108-025-02011-2.
  19. Kochman M. Primary hyperparathyroidism: clinical manifestations, diagnosis and evaluation according to the Fifth International Workshop guidelines. Reumatologia. 2023;61(4):256–63. DOI: 10.5114/reum/170705
  20. Liu X, Li B, Liu J, Zhao S. Severe acute pancreatitis induced by primary hyperparathyroidism in pregnancy: a case report and literature review. J Surg Case Rep. 2025 Mar 28;2025(4):rjaf161. DOI: 10.1093/jscr/rjaf161
  21. Pal R, Mukherjee S, Prasad TN, Bhadada SK. Pregnancy with primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2025 Mar;39(2):101983. DOI: 10.1016/j.beem.2025.101983
  22. “On approval of the Standards of medical care ‘Normal pregnancy’” [Internet]. Ministry of Health of Ukraine, 2022. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukraini-vid-09082022--1437-pro-zatverdzhennja-standartiv-medichnoi-dopomogi-normalna-vagitnist
  23. Order of the Ministry of Health of Ukraine dated 17.04.25 No. 667 Standard of medical care “Nausea and vomiting during pregnancy. Excessive vomiting of pregnancy” [Internet]. Ministry of Health of Ukraine, 2025. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukrayini-vid-17-04-2025-667-pro-zatverdzhennya-standartu-medichnoyi-dopomogi-nudota-i-blyuvannya-pid-chas-vagitnosti-nadmirne-blyuvannya-vagitnih
  24. «On approval of the Unified Clinical Protocol of Primary, Secondary (Specialized) and Tertiary (Highly Specialized) Medical Care «Hypertensive Disorders During Pregnancy and the Postpartum Period».[Internet]. Ministry of Health of Ukraine, 2022. Available from: https://moz.gov.ua/uk/decrees/nakaz-moz-ukraini-vid-24012022--151-pro-zatverdzhennja-unifikovanogo-klinichnogo-protokolu-pervinnoi-vtorinnoi-specializovanoi-ta-tretinnoi-visok-ospecializovanoi-medichnoi-dopomogi-gipertenzivni-rozladi-pid-chas-vagitnosti.
  25. van der Leij S, Hertog D. Hypercalcemia in Pregnancy Caused by a Uterine Myoma. JCEM Case Rep. 2024 Aug 14;2(9):luae126. DOI: 10.1210/jcemcr/luae126.
  26. Xu Y, Yu Y. Primary hyperparathyroidism presenting as a brown tumor with hypercalcemia crisis in a second-trimester pregnant woman: A case report. Medicine (Baltimore). 2021 May 21;100(20):e25968. DOI: 10.1097/MD.0000000000025968
  27. Tsourdi E, Anastasilakis AD. Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature. Biomedicines. 2021 Apr 26;9(5):475. DOI: 10.3390/biomedicines9050475
  28. Matikainen N. Guideline 00502. Hypercalcemia and hyperparathyroidism [Internet]. Ministry of Health of Ukraine, 2018. Available from: http://guidelines.moz.gov.ua/documents/2918?id=ebm00502$Format=pdf.
  29. Palermo A, Tabacco G, Makras P, Zavatta G, Trimboli P, Castellano E, et al. Primary hyperparathyroidism: from guidelines to outpatient clinic. Rev Endocr Metab Disord. 2024 Oct;25(5):875–96. DOI: 10.1007/s11154-024-09899-5
  30. Sell J, Ramirez S, Partin M. Parathyroid Disorders. Am Fam Physician. 2022 Mar 1;105(3):289–98.
  31. Kassi E, Adamidou F, Yavropoulou MP, Anastasilakis AD, Makras P, Vryonidou A, Tournis S. Diagnosis and management of hypoparathyroidism: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. Hormones (Athens). 2025 Dec;24(4):913–22. DOI: 10.1007/s42000-025-00693-9.
  32. Kamenicky P, Mirallie E, Hindie E, Vantyghem MC, Brunaud L. Chapter 0: Introduction to the consensus on primary hyperparathyroidism from the French Society of Endocrinology, French speaking Association of Endocrine Surgery and French Society of Nuclear Medicine. Ann Endocrinol (Paris). 2025 Feb;86(1):101689. DOI: 10.1016/j.ando.2025.101689
  33. Makarov I. Rare clinical observations of surgical treatment of large parathyroid adenomas. Problems of endocrine pathology. 2021;64(2):46–50. DOI: https://doi.org/10.21856/j-PEP.2018.2.07
  34. Denysenko A, Cherniy V, Tkachenko R. Issues of treatment of secondary hyperparathyroidism through the eyes of an anesthesiologist. Experience of perioperative anesthetic support and intensive care in parathyroid surgery. Clinical and Preventive Medicine. 2021;2:4 –16. DOI: https://doi.org/10.31612/2616-4868.2(16).2021.01.
  35. Milat F, Ramchand SK, Herath M, Gundara J, Harper S, Farrell S, et al. Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. Clin Endocrinol (Oxf). 2024 Jan;100(1):3–18. DOI: 10.1111/cen.14659.
  36. Tagieva, N, Erokhovych V. Primary hyperparathyroidism on the background of D-deficiency. Ukrainian Scientific Medical Youth Journal. 2025;2 (154):103 –7. DOI: https://doi.org/10.32345/USMYJ.2(154).2025.103-107
  37. Karachentsev YI, Sazonov ME, Khaziyev VV, Dubovik V, Goncharova O, Gopkalova I. Diagnosis and treatment of primary hyperparathyroidism (own 20-year experience and literature review). International Endocrinological Journal. 2021;5(17):11 –8. DOI: https://doi.org/10.22141/2224-0721.17.5.2021.241515.
  38. Stadnik AV, Grekh AG, Kovalyk PA, Kulbitska V. Chronic renal failure: vitamin D deficiency and secondary hyperparathyroidism. Perspectives and innovations of science. 2025; 12(58):2890 –9. DOI: https://doi.org/10.52058/2786-4952-2025-12(58)-2890-2899 39.
  39. Wan QC, Li JF, Tang LL, Lv J, Xie LJ, Li JP, et al. Comparing the diagnostic accuracy of 4D CT and 99mTc-MIBI SPECT/CT for localizing hyperfunctioning parathyroid glands: a systematic review and meta-analysis. Nucl Med Commun. 2021 Mar 1;42(3):225–33. DOI: 10.1097/MNM.0000000000001331
  40. Martynyuk LP, Shershun OI, Malsk TL. Effectiveness of combined treatment of secondary hyperparathyroidism in patients with chronic kidney disease in the predialysis period. Pain, joints, spine. 2023;13(1):38 –45. DOI: https://doi.org/10.22141/pjs.13.1.2023.356
  41. Nastos C, Paspala A, Mavroeidi I, Stavratis F, Lampadiari V, Kalantaridou S, et al. Surgical management of primary hyperparathyroidism during pregnancy: a systematic review of the literature. Gynecol Endocrinol. 2021 Dec;37(12):1086–95. DOI: 10.1080/09513590.2021.1932801
  42. Perrier N, Lang BH, Farias LCB, Poch LL, Sywak M, Almquist M, et al. Surgical Aspects of Primary Hyperparathyroidism. J Bone Miner Res. 2022 Nov;37(11):2373–90. DOI: 10.1002/jbmr.4689

Downloads

Published

2026-04-18

How to Cite

Mishchenko, V., Gladchuk, I., & Mishchenko, V. (2026). Features of assessing the condition of pregnant women with parathyroid adenoma: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (82), 26–33. https://doi.org/10.18370/2309-4117.2026.82.26-33

Issue

No. 82 (2026)

Section

Pregnancy and childbirth

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.